Committed to developing innovative solutions
Silo Pharma Inc. is a developmental stage biopharmaceutical company focused on developing traditional therapeutics and psychedelic medicine. The company concentrates on the development and commercialization of therapies for unmet needs. The Company’s lead program SPC-15 is an intranasal formulation targeting the 5-HT(4) receptor agonist for the treatment of PTSD and stress-induced anxiety disorder. SP-26 is a ketamine-based injectable dissolvable implant for the treatment of chronic pain and fibromyalgia. The subcutaneous implant safely regulates dosage and time release. Silo Pharma’s preclinical programs include SPC-14, an intranasal compound for the treatment of patients with Alzheimer’s disease (AD), and SPU-16, a treatment for central nervous system disorders.
The Silo difference
We are committed to developing innovative solutions to address a variety of underserved conditions including Alzheimer’s; Fibromyalgia; and Stress-Induced Psychiatric Disorders.
While partnering with some of the leading Academic Institutions Silo has licensed therapeutics that will allow the company to pursue the more streamlined 505(b)(2) route for trials.
Silo anticipates this strategy will lower cost and allow for a faster approval process to help patients with few if any proven addressable therapeutics.